In the pharmaceutical industry, Lisinopril 2.5 mg is an ACE (Angiotensin-Converting Enzyme) Inhibitor. As a pharmacist, I view the 2.5 mg strength as the critical “initiation dose.” It is used to carefully start treatment in patients who may be sensitive to blood pressure changes, such as the elderly or those on high-dose diuretics, to avoid a sudden drop in blood pressure (first-dose hypotension).

Primary Clinical Uses

• Hypertension (High Blood Pressure): Used as a starting dose to gradually lower blood pressure. It is often titrated upward to 10 mg or 20 mg for long-term maintenance.

• Heart Failure: Administered as an adjunctive therapy to improve survival and reduce hospitalizations by easing the workload on the heart.

• Post-Myocardial Infarction (Heart Attack): Given within 24 hours of a heart attack to improve hemodynamics and prevent the heart muscle from weakening (remodeling).

• Diabetic Nephropathy: Prescribed to protect kidney function in diabetic patients by reducing the pressure in the small blood vessels of the kidneys.

Mechanism of Action: The RAAS Pathway

Lisinopril belongs to the dicarboxylic acid-containing group of ACE inhibitors. Unlike many others, it is not a prodrug and does not require liver metabolism to become active.

Enzyme Blockade: It inhibits the enzyme responsible for converting Angiotensin I into Angiotensin II (a powerful vasoconstrictor).

Vasodilation: By reducing Angiotensin II, it allows the blood vessels to relax and widen.

Aldosterone Reduction: It lowers the secretion of aldosterone, which decreases sodium and water retention, thereby reducing the total blood volume.

Kidney Protection: It specifically dilates the efferent arteriole in the kidney, lowering intraglomerular pressure.

The Manufacturer’s Perspective: Technical & Export

From a manufacturing standpoint in a WHO-GMP facility, Lisinopril 2.5 mg presents specific professional requirements:

• Content Uniformity: Achieving a precise 2.5 mg distribution in a standard-sized tablet requires high-precision blending and validated geometric dilution to ensure every tablet in a batch is therapeutically identical.

• Stability & Sensitivity: Lisinopril is sensitive to moisture and can undergo cyclization to form diketopiperazine. We utilize Alu-Alu or high-barrier PVC/PVDC blister packaging to ensure a 36-month shelf life for export to Zone IVb regions.

• Bioequivalence: As a manufacturer, we provide dissolution profiles comparing our generic to the innovator (Zestril or Prinivil) to ensure B2B buyers of its efficacy.

• Dossier Availability: Our Mumbai facility maintains full CTD/eCTD Dossiers to support rapid product registration in international markets.